LobbyingDragonfly Therapeutics lobbying by quarter
Dragonfly Therapeutics's latest lobbying report covers Q1 2026, at under $5,000. The four quarters Q3 2025–Q2 2026 total $30K. Its first report covers Q1 2024; the issues it reports most are Taxation/Internal Revenue Code.
Dragonfly Therapeutics
- Latest quarter
- No record
- Q2 2026 · 0 reports
- Last 12 months
- $30K
- Last 4 quarters
- vs last quarter
- No record
- Q2 2026 against the quarter before
- First report
- Q1 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2024 | $30K | 1 |
| Q2 2024 | $20K | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $30K | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 0 |
Policy issues the reports name
- Taxation3 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
Firms it paid
| Firm | ||
|---|---|---|
| FGS Global | $80K | 5 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 04/14for Q1 | FGS Global | Under $5,000 |
| 01/20for Q4 2025 | FGS Global | $30K |
| 25/10/23for Q4 2025 | FGS Global | Under $5,000 |
| 25/10/23for Q4 2025 | FGS Global | Under $5,000 |
| 24/10/17for Q3 2024 | FGS Global | Under $5,000 |
| 24/07/17for Q2 2024 | FGS Global | $20K |
| 24/04/22for Q1 2024 | FGS Global | $30K |
| 24/03/28for Q1 2024 | FGS Global | Under $5,000 |